Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphodiesterase 3B (PDE3B) is an enzyme that belongs to the PDE3 family. It regulates the intracellular concentrations of cyclic nucleotides, cAMP and cGMP, by catalyzing their hydrolysis. PDE3B is highly expressed in tissues involved in energy metabolism such as hepatocytes, brown and white adipocytes, and pancreatic β cells. It regulates key metabolic processes including lipolysis, glucose uptake, and insulin secretion, making it a potential therapeutic target for metabolic disorders like obesity and type II diabetes mellitus. Its involvement in cardiovascular function further broadens its clinical relevance. Alterations in PDE3B have been linked to conditions like primary aldosteronism and vitamin D hydroxylation-deficient rickets type 1b. circRNA forms of this gene have been implicated in cancer progression.
PDE3B inhibitors increase intracellular cAMP and cGMP levels by preventing their degradation, leading to various downstream effects depending on the tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphodiesterase 3B (None).